SCENTMATIC
8.4.2024 11:32:26 CEST | Business Wire | Press release
SCENTMATIC Inc (CEO: Toshiharu Kurisu, Head office: Tokyo, Japan), which proposes new customer experiences through the digitization of fragrance, announced that their AI service that verbalizes fragrance KAORIUM has been selected as “Retracing innovation and ideas that defined the lifestyle trends of 2023” by STIRworld.com, a leading global digital magazine in the fields of design, architecture, and arts.
* KAORIUM is a registered trademark of SCENTMATIC Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328876250/en/
What's KAORIUM? Read scents, smell words; A journey of fragrance discovery that ignites the olfactory imagination. Finding a perfume is a challenge. Fragrances are hard to grasp, and expressing our preferences can be tough. KAORIUM by SCENTMATIC is an entirely novel approach to fragrance exploration that decodes the enigmatic world of scents and helps people discover new fragrances intuitively through language. Harnessing state-of-the-art technology, our mission is to deliver olfactory moments of delight. When a scent is placed on the coaster, the impression of the scent is visualized in words. By expressing sensory perceptions through language, scents that were once difficult to discern become more clearly perceivable. (Graphic: Business Wire)
STIRworld.com Article page (Published 17 December 2023)
“Retracing innovation and ideas that defined the lifestyle trends of 2023”
https://www.stirworld.com/see-features-retracing-innovation-and-ideas-that-defined-the-lifestyle-trends-of-2023
The article introduces KAORIUM as one of the lifestyle trends that will have a major impact on the global design structure in 2023. The article describes KAORIUM’s process of scent, language, and artificial intelligence uniting to refine the user's scent preferences as “an immersive experience”. KAORIUM was highly evaluated as a lifestyle trend for 2023, defining a new retail experience that cannot be found in traditional perfume selling counters.
About KAORIUM
https://www.youtube.com/embed/0fpDr3zgjeM?feature=oembed
The article was also featured on the Instagram account of STIRworld.com.
STIRworld.com Instagram reel video (Posted on 20 December 2023)
https://www.instagram.com/reel/C1CqKsNywAD/?igsh=cXJxczUzanhxa2to
KAORIUM was in the spotlight when we exhibited this AI system that mutually converts scents and words at the London Design Festival 2023, one of the world's leading design events, held in London, UK, for eight days from 16 to 24 September 2023.
STIRworld.com Article page (Published on 19 September 2023)
https://www.stirworld.com/see-lifestyle-scentmatics-kaorium-at-ldf-2023-explores-language-and-emotion-in-fragrance-selection
In the interview with STIR, Kurisu, Managing Director of SCENTMATIC, introduced the innovations brought by KAORIUM to the Japanese retail industry, as well as its future potential and social impact.
GET IN TOUCH
https://scentmatic.co.jp/contact-en
[SCENTMATIC, Inc.]
SCENTMATIC was established in 2019 as a co-creation fragrance business design group that can add "emotional experience value" to everything using an AI system that verbalizes fragrance. Focusing on the most unknown area of the five senses “smell”, we have developed KAORIUM, an AI tool that verbalizes fragrance. KAORIUM is expected to help businesses to utilize fragrance in a variety of ways. SCENTMATIC is working on the 'digitalization of the sense of smell'. It will revolutionize business in all industries by evolving people's senses through the 'experience of smell' using fragrance and words.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328876250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom